Melissa B Epperly insider trades

Open-market stock purchases and sales by Melissa B Epperly, Director at Roivant Sciences Ltd, from SEC Form 4 filings since Apr 7, 2020.

Track record: 0% of 3 scored buys are up 5% or more since purchase, averaging -88%.

Recent trades

DateStockTradeValue
Sep 16, 2026ROIV Roivant Sciences LtdBought (not open market)—
Sep 16, 2026ROIV Roivant Sciences LtdBought (not open market)—
Sep 15, 2026ROIV Roivant Sciences LtdSold$172K
Sep 15, 2026ROIV Roivant Sciences LtdSold$24.2K
Sep 10, 2026ROIV Roivant Sciences LtdSold (not open market)$89.2K
Jun 18, 2026NAUT Nautilus Biotechnology, IncBought (not open market)—
Apr 17, 2026ROIV Roivant Sciences LtdBought (not open market)—
Mar 16, 2026ROIV Roivant Sciences LtdSold$1.2M
Jan 20, 2026ROIV Roivant Sciences LtdBought (not open market)—
Jan 20, 2026ROIV Roivant Sciences LtdSold (not open market)$1.2K
Oct 20, 2025ROIV Roivant Sciences LtdBought (not open market)—

Companies traded

  • ROIV Roivant Sciences Ltd: 3 sales, last Sep 16, 2026
  • NAUT Nautilus Biotechnology, Inc: other filings, last Jun 18, 2026
  • KNTE Kinnate Biopharma Inc: other filings, last Apr 3, 2024
  • ZNTL Zentalis Pharmaceuticals, Inc: 3 buys, 46 sales, last Feb 12, 2024

Get free alerts when Melissa B Epperly files a new trade →